Summary
Fibrocell Science Inc (Fibrocell Science) is an autologous cell and gene therapy company which discovers and develops therapies for diseases affecting the skin and connective tissue. The company’s product pipeline comprises FCX-007, a lead candidate for the treatment of recessive dystrophic epidermolysis bullosa; FCX-013 for linear scleroderma; and a research program for the treatment of arthritis and related conditions. Fibrocell Science utilizes its proprietary autologous fibroblast technology to develop personalized biologics for skin diseases. It has a manufacturing facility in Exton, Pennsylvania; and operates along with its subsidiaries in the US and Switzerland. Fibrocell Science is headquartered in Exton, Pennsylvania, the US.
Fibrocell Science Inc (FCSC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Fibrocell Science Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Fibrocell Science Inc, Medical Devices Deals, 2011 to YTD 2017 10
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Fibrocell Science Enters into Agreement with Intrexon 12
Fibrocell Science And Intrexon Expand Co-Development Agreement For Hypermobility-Type Ehlers-Danlos Syndrome 12
Fibrocell Science And Intrexon Expand Co-Development Agreement For Potential New Class Of Therapeutics 14
Fibrocell Science Enters Into Co-Development Agreement With Intrexon 15
Licensing Agreements 16
Fibrocell Science Enters into Licensing Agreement with Intrexon 16
Fibrocell Science Enters into Licensing Agreement with University of California to Advance the Development of Personalized Cell Therapies 18
Fibrocell Science Enters Into Licensing Agreement With University of California 19
Equity Offering 20
Fibrocell Science to Raise USD8 Million in Private Placement of Series A Preferred Stock and Warrants 20
Fibrocell Science to Raise up to USD50 Million in Public Offeirng of Shares 21
Fibrocell Raises USD17.4 Million in Public Offering of Shares 22
Fibrocell Science Completes Underwriters Exercise Of Partial Over-Allotment Option Of Public Offering Of Shares For US$50.5 Million 23
Fibrocell Science Completes Private Placement Of Shares For US$45 Million 25
Fibrocell Science Completes Second Tranche Of Private Placement For US$5.8 Million 26
Fibrocell Science Completes Private Placement Of Common Stock For US$22.8 Million 27
Fibrocell Science Completes Final Tranche Of Private Placement For US$3.4 Million 28
Debt Offering 29
Fibrocell Science Raises USD18.1 Million in Private Placement of Notes and Warrants 29
Acquisition 30
Rohto Pharma Completes Acquisition Of 57% Stake In Agera Labs, Skincare Company 30
Fibrocell Science Inc - Key Competitors 32
Key Employees 33
Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Financial Announcements 35
May 10, 2017: Fibrocell Reports First Quarter 2017 Financial Results and Recent Operational Highlights 35
Mar 09, 2017: Fibrocell Reports 2016 Financial Results and Recent Operational Highlights 36
Nov 03, 2016: Fibrocell Reports Third Quarter 2016 Financial Results and Recent Operational Highlights 38
Aug 04, 2016: Fibrocell Reports Second Quarter 2016 Financial Results and Recent Operational Highlights 40
May 05, 2016: Fibrocell Reports First Quarter 2016 Financial Results and Operational Highlights 42
Mar 10, 2016: Fibrocell Reports Fourth Quarter and Full Year 2015 Financial Results and Operational Highlights 44
Corporate Communications 46
Dec 19, 2016: Fibrocell Announces Leadership Changes 46
Product News 47
Jun 29, 2016: Fibrocell Announces Update on FCX-007 47
Product Approvals 48
Apr 18, 2016: Fibrocell and Intrexon Announce Allowance to Commence Phase I/II Trial for FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa 48
Other Significant Developments 49
Jan 27, 2016: Fibrocell Highlights Recent Pipeline Accomplishments 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50
List of Tables
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Fibrocell Science Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Fibrocell Science Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Fibrocell Science Inc, Medical Devices Deals, 2011 to YTD 2017 10
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Fibrocell Science Enters into Agreement with Intrexon 12
Fibrocell Science And Intrexon Expand Co-Development Agreement For Hypermobility-Type Ehlers-Danlos Syndrome 12
Fibrocell Science And Intrexon Expand Co-Development Agreement For Potential New Class Of Therapeutics 14
Fibrocell Science Enters Into Co-Development Agreement With Intrexon 15
Fibrocell Science Enters into Licensing Agreement with Intrexon 16
Fibrocell Science Enters into Licensing Agreement with University of California to Advance the Development of Personalized Cell Therapies 18
Fibrocell Science Enters Into Licensing Agreement With University of California 19
Fibrocell Science to Raise USD8 Million in Private Placement of Series A Preferred Stock and Warrants 20
Fibrocell Science to Raise up to USD50 Million in Public Offeirng of Shares 21
Fibrocell Raises USD17.4 Million in Public Offering of Shares 22
Fibrocell Science Completes Underwriters Exercise Of Partial Over-Allotment Option Of Public Offering Of Shares For US$50.5 Million 23
Fibrocell Science Completes Private Placement Of Shares For US$45 Million 25
Fibrocell Science Completes Second Tranche Of Private Placement For US$5.8 Million 26
Fibrocell Science Completes Private Placement Of Common Stock For US$22.8 Million 27
Fibrocell Science Completes Final Tranche Of Private Placement For US$3.4 Million 28
Fibrocell Science Raises USD18.1 Million in Private Placement of Notes and Warrants 29
Rohto Pharma Completes Acquisition Of 57% Stake In Agera Labs, Skincare Company 30
Fibrocell Science Inc, Key Competitors 32
Fibrocell Science Inc, Key Employees 33
Fibrocell Science Inc, Subsidiaries 34List of Figures
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Fibrocell Science Inc, Medical Devices Deals, 2011 to YTD 2017 10
